



Drug Evaluation Committee



The Drug Evaluation Committee (DEC) is an internal group drawn from ESI Canada's doctors of pharmacy, pharmacists, pharmacy technicians, and claim professionals. The DEC can also draw on the resources of Express Scripts to assess the impact of new drugs which have been marketed in the United States before they are marketed in Canada.

As part of its responsibilities, the DEC also reviews and makes recommendations on new drug strategies, budget impact analysis, drug plan management strategies, and new technology assessment and coverage. The DEC communicates its findings to ESI Canada's customers for them to use as appropriate with their group benefits programs.

*Redefining
Health Claims
Solutions*

THOUGHT LEADERSHIP IN MANAGING DRUG PLANS

The DEC is committed to promoting the health of patients with compassion, respect and professionalism. By understanding the needs of plan sponsors, the DEC can assist in providing strategies for drug coverage before or soon after a new drug enters the Canadian market.

Please note: ESI Canada offers its customers different products. It is our customers who decide which of these products will be offered through their own branded programs. Some products may not be available in all provinces/territories.



ESI CANADA®

www.esi-canada.com